• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

补体抑制剂依库珠单抗治疗血栓性微血管病：单中心病例系列

Complement inhibitor eculizumab in thrombotic microangiopathy: Single-center case series.

作者信息

Vitkauskaitė Monika, Vinikovas Artūras, Miglinas Marius, Rimševičius Laurynas, Čerkauskaitė Agnė, Mačionienė Ernesta, Ašakienė Eglė

机构信息

Faculty of Medicine Vilnius University Vilnius Lithuania.

Clinic of Gastroenterology, Nephro-Urology and Surgery Faculty of Medicine Institute of Clinical Medicine Vilnius University Vilnius Lithuania.

出版信息

Clin Case Rep. 2022 Mar 15;10(3):e05573. doi: 10.1002/ccr3.5573. eCollection 2022 Mar.

DOI:10.1002/ccr3.5573
PMID:35317070
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8922540/
Abstract

Our case series showed that eculizumab is efficacious and safe in treating thrombotic microangiopathy, as well as it has positive effects on quality of life. Further extensive studies are required to develop unified treatment guidelines.

摘要

我们的病例系列研究表明，依库珠单抗在治疗血栓性微血管病方面有效且安全，并且对生活质量有积极影响。需要进一步开展广泛研究以制定统一的治疗指南。

相似文献

1
Complement inhibitor eculizumab in thrombotic microangiopathy: Single-center case series.补体抑制剂依库珠单抗治疗血栓性微血管病：单中心病例系列
Clin Case Rep. 2022 Mar 15;10(3):e05573. doi: 10.1002/ccr3.5573. eCollection 2022 Mar.
2
Postpartum thrombotic microangiopathy revealed as atypical hemolytic uremic syndrome successfully treated with eculizumab: a case report.产后血栓性微血管病表现为非典型溶血性尿毒症综合征，用依库珠单抗成功治疗：一例报告
J Med Case Rep. 2014 Sep 14;8:307. doi: 10.1186/1752-1947-8-307.
3
Atypical hemolytic uremic syndrome in first trimester pregnancy successfully treated with eculizumab.妊娠早期非典型溶血性尿毒症综合征经依库珠单抗成功治疗。
Exp Hematol Oncol. 2017 Jan 13;6:4. doi: 10.1186/s40164-017-0064-7. eCollection 2017.
4
Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome.依库珠单抗治疗非典型溶血尿毒综合征。
N Engl J Med. 2013 Jun 6;368(23):2169-81. doi: 10.1056/NEJMoa1208981.
5
A case-based narrative review of pregnancy-associated atypical hemolytic uremic syndrome/complement-mediated thrombotic microangiopathy.妊娠相关性非典型溶血尿毒综合征/补体介导的血栓性微血管病的病例叙述性综述。
Kidney Int. 2024 May;105(5):960-970. doi: 10.1016/j.kint.2023.12.021. Epub 2024 Feb 24.
6
The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment.长效 C5 抑制剂 ravulizumab 对补体抑制剂治疗初治的儿童非典型溶血尿毒症综合征患者有效且安全。
Kidney Int. 2021 Jul;100(1):225-237. doi: 10.1016/j.kint.2020.10.046. Epub 2020 Dec 8.
7
The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment.长效C5抑制剂ravulizumab在未接受过补体抑制剂治疗的非典型溶血性尿毒症综合征成年患者中有效且安全。
Kidney Int. 2020 Jun;97(6):1287-1296. doi: 10.1016/j.kint.2020.01.035. Epub 2020 Mar 6.
8
[Ocular thrombotic microangiopathy in atypical hemolytic-uremic syndrome (a clinical case study)].[非典型溶血尿毒综合征中的眼部血栓性微血管病（一项临床病例研究）]
Vestn Oftalmol. 2018;134(5. Vyp. 2):215-226. doi: 10.17116/oftalma2018134051215.
9
When to Stop Eculizumab in Complement-Mediated Thrombotic Microangiopathies.补体介导的血栓性微血管病何时停用依库珠单抗。
Am J Nephrol. 2018;48(2):96-107. doi: 10.1159/000492033. Epub 2018 Aug 15.
10
Efficacy and safety of eculizumab in adult patients with atypical hemolytic uremic syndrome: A single center experience from Turkey.依库珠单抗治疗非典型溶血性尿毒症综合征成年患者的疗效与安全性：来自土耳其的单中心经验
Transfus Apher Sci. 2016 Dec;55(3):357-362. doi: 10.1016/j.transci.2016.09.017. Epub 2016 Sep 30.

本文引用的文献

1
Thrombotic Microangiopathy, an Unusual Form of Monoclonal Gammopathy of Renal Significance: Report of 3 Cases and Literature Review.血栓性微血管病，一种具有肾脏意义的单克隆丙种球蛋白病的罕见形式：3例报告及文献综述
Front Immunol. 2021 Nov 10;12:780107. doi: 10.3389/fimmu.2021.780107. eCollection 2021.
2
Atypical hemolytic uremic syndrome in Brazil: clinical presentation, genetic findings and outcomes of a case series in adults and children treated with eculizumab.巴西非典型溶血尿毒综合征：接受依库珠单抗治疗的成人和儿童病例系列的临床表现、基因研究结果及预后
Clin Kidney J. 2020 Jun 22;14(4):1126-1135. doi: 10.1093/ckj/sfaa062. eCollection 2021 Apr.
3
Eculizumab use in a tertiary care nephrology center: data from the Vienna TMA cohort.依库珠单抗在三级肾病护理中心的使用：来自维也纳 TMA 队列的数据。
J Nephrol. 2022 Mar;35(2):451-461. doi: 10.1007/s40620-021-00981-8. Epub 2021 Feb 18.
4
Epidemiology of Atypical Hemolytic Uremic Syndrome: A Systematic Literature Review.非典型溶血尿毒综合征的流行病学：一项系统文献综述
Clin Epidemiol. 2020 Mar 12;12:295-305. doi: 10.2147/CLEP.S245642. eCollection 2020.
5
Eculizumab Safety: Five-Year Experience From the Global Atypical Hemolytic Uremic Syndrome Registry.依库珠单抗安全性：来自全球非典型溶血性尿毒症综合征注册研究的五年经验
Kidney Int Rep. 2019 Aug 2;4(11):1568-1576. doi: 10.1016/j.ekir.2019.07.016. eCollection 2019 Nov.
6
Outcomes in patients with atypical hemolytic uremic syndrome treated with eculizumab in a long-term observational study.在一项长期观察性研究中，用依库珠单抗治疗非典型溶血尿毒综合征患者的结果。
BMC Nephrol. 2019 Apr 10;20(1):125. doi: 10.1186/s12882-019-1314-1.
7
Eculizumab Use for Kidney Transplantation in Patients With a Diagnosis of Atypical Hemolytic Uremic Syndrome.依库珠单抗用于诊断为非典型溶血性尿毒症综合征患者的肾脏移植
Kidney Int Rep. 2018 Dec 3;4(3):434-446. doi: 10.1016/j.ekir.2018.11.010. eCollection 2019 Mar.
8
Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab.依库珠单抗的药理学、药代动力学和药效学，以及依库珠单抗个体化治疗的可能性。
Clin Pharmacokinet. 2019 Jul;58(7):859-874. doi: 10.1007/s40262-019-00742-8.
9
Optimal duration of treatment with eculizumab in atypical hemolytic uremic syndrome (aHUS)-a question to be addressed in a scientific way.依库珠单抗治疗非典型溶血性尿毒症综合征（aHUS）的最佳疗程——一个有待以科学方式解决的问题。
Pediatr Nephrol. 2019 May;34(5):943-949. doi: 10.1007/s00467-019-4192-7. Epub 2019 Jan 28.
10
Secondary thrombotic microangiopathy in systemic lupus erythematosus and antiphospholipid syndrome, the role of complement and use of eculizumab: Case series and review of literature.系统性红斑狼疮和抗磷脂综合征中的继发性血栓性微血管病、补体的作用及依库珠单抗的应用：病例系列及文献复习。
Semin Arthritis Rheum. 2019 Aug;49(1):74-83. doi: 10.1016/j.semarthrit.2018.11.005. Epub 2018 Dec 4.